Idorsia (IDIA.SW) Osake Kurssi
Idorsia Kurssi
Viimeisten 8 vuoden aikana Idorsian liikevaihto kasvoi 4,3 % vuodessa ja ylsi 221,00 M CHF:een. Idorsian nettomarginaali −50,7 % on noussut verrattuna −1 795,2 %:iin muutama vuosi sitten. Idorsian 12 kuukauden konsensustavoitehinta on 4,59 CHF, noin yli kurssia 17,5 %. 10 analyytikosta 7 suosittaa ostoa — kokonaiskonsensus on Osta.
Idorsia osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Idorsia liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Idorsia -osakkeesta
The business model of Idorsia Ltd revolves around the research, development, and commercialization of innovative pharmaceutical products. As a biopharmaceutical company, Idorsia focuses on discovering breakthrough therapies to address unmet medical needs. By leveraging its expertise in drug discovery and clinical development, Idorsia aims to bring novel treatments to patients worldwide. The company operates through collaborations with partners, strategic alliances, and the advancement of its own pipeline. With a commitment to scientific excellence and patient-centricity, Idorsia strives to improve the quality of life for individuals through the development of effective and safe medications.
Idorsia Ltd is primarily active in the pharmaceutical industry.
The main competitors of Idorsia Ltd in the market include big pharmaceutical companies such as Novartis, Roche, Pfizer, and GlaxoSmithKline. These companies also operate in the pharmaceutical industry and offer a range of products and services similar to Idorsia Ltd. Being a relatively new player in the market, Idorsia Ltd faces tough competition from these well-established competitors. However, Idorsia Ltd aims to differentiate itself through its innovative pharmaceutical pipeline and focus on developing novel treatments for various therapeutic areas.
Idorsia Ltd is a Swiss biopharmaceutical company specializing in the discovery, development, and commercialization of innovative therapeutic solutions. Founded in 2017 as a spin-off from Actelion Ltd, Idorsia boasts a rich history and strong foundation in the pharmaceutical industry. Building on the legacy of its predecessor, Idorsia has rapidly emerged as a key player in the development of novel treatments for various diseases and disorders. Led by an experienced management team, the company combines cutting-edge research with a focus on patient outcomes, striving to improve the lives of individuals worldwide. With its commitment to innovation and scientific excellence, Idorsia continues to make significant contributions to the field of biopharmaceuticals.
Idorsia Ltd has achieved several significant milestones in its history. The company, founded by renowned pharmaceutical entrepreneur Jean-Paul Clozel, made its debut on the SIX Swiss Exchange in June 2017. Since then, Idorsia has made remarkable progress in its drug development pipeline. One of the notable achievements of the company is the successful completion of Phase 3 clinical trials for their leading compound, daridorexant, a potential treatment for insomnia. Furthermore, Idorsia has also received regulatory approvals for the commercialization of several drugs, strengthening its presence in the pharmaceutical market. These achievements demonstrate Idorsia Ltd's commitment to innovation and its potential for future growth.
Idorsia Ltd is primarily present in Switzerland, where its headquarters are located. Aside from its domestic market, Idorsia has a global presence with operations and activities in various countries and regions. The company's focus on research and development of innovative therapies extends beyond Switzerland, reaching international markets. With a commitment to expanding its reach, Idorsia actively engages in collaborations, partnerships, and licensing agreements to further establish its presence worldwide. As a Swiss-based pharmaceutical company, Idorsia Ltd's prominence extends both locally and internationally as it strives to deliver groundbreaking medical solutions.
Idorsia Ltd represents a corporate philosophy focused on innovation, collaboration, and patient-centric healthcare. The company values excellence, integrity, and scientific rigor in all aspects of its operations. Idorsia is committed to developing breakthrough therapies and improving the lives of patients worldwide. With a strong emphasis on research and development, the company strives to deliver innovative solutions to unmet medical needs. By fostering a culture of continuous learning and teamwork, Idorsia aims to make a positive impact on the healthcare industry and contribute to the advancement of medicine.
Analyytikot asettavat tällä hetkellä Idorsia-osakkeelle keskimääräisen tavoitehinnan 4,59 CHF (mediaani: 4,59 CHF), mikä merkitsee +17,5 % viimeisimpään hintaan verrattuna. Konsensus perustuu 10 analyytikkoarvioon.
10 analyytikkoa arvioi tällä hetkellä Idorsia-osaketta: 7 suosittaa ostoa, 3 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Idorsia-yhtiöltä 221,20 M CHF liikevaihtoa ja −0,53 CHF osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Idorsia-osake noteerataan hintaan 4,22 EUR (3,91 CHF).
Idorsia-osake (IDIA.SW) on listattuna 7 pörssissä, muun muassa: London (0RQE.L), SIX (Zürich) (IDIA.SW), Frankfurt (19T.F), München (19T.MU), Düsseldorf (19T.DU), Hamburg (19T.HM).
Idorsia Ltd is a biopharmaceutical company based in Switzerland that focuses on the discovery, development, and commercialization of innovative therapies for mental and neurological disorders. The company consists of three main divisions: research and development, operations, and business development. The research and development division focuses on the discovery of new drugs and therapies for mental and neurological disorders, while operations is responsible for manufacturing and marketing the medications. Business development is involved in identifying potential business opportunities and developing partnerships and strategic alliances. Idorsia's core product is the insomnia medication Daridorexant. Daridorexant is a non-addictive medication that specifically targets the nerves in the brain to regulate the sleep-wake cycle. The medication has been proven to be safe and effective in clinical trials and is currently being submitted for approval by regulatory authorities. In addition to Daridorexant, Idorsia has a number of other medications in development that focus on various diseases and indications. The company is currently working on therapies for conditions such as schizophrenia, anxiety disorders, depression, and Alzheimer's disease. Idorsia is also working on a technology platform based on the identification of target molecules and the acceleration of drug development. This platform allows the company to develop new medications faster and more efficiently, ultimately leading to faster market release. To expand its product pipeline, Idorsia has also entered into several strategic alliances and partnerships with other biopharmaceutical companies. One such partnership is the collaboration with Japanese company Kyowa Kirin, where the two companies will focus on the development of therapies for severe sleep disorders. Idorsia utilizes an innovative business model designed to create value by reducing costs and risks in drug development. The company has a broad pipeline of drug candidates at various stages of development, from discovery to clinical development. This allows the company to achieve portfolio diversification and mitigate the risk of revenue loss. In summary, Idorsia is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for mental and neurological disorders. With an extensive portfolio of therapies and an innovative technology platform, the company is well-positioned to bring valuable medications to market that improve people's lives.
odotettu liikevaihto Idorsia on 221,20 M CHF. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Idorsia on −131,36 M CHF. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Idorsia:n hinta-voitto-suhde (P/E) on tällä hetkellä −7,39. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Idorsia-osakkeen arvostusta.
Idorsia:n hinta-myynti-suhde (P/S) on tällä hetkellä 4,39. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Idorsia-osakkeen arvostuskennuslukuna.
Idorsia:n Eulpool-laatuscore on 3/10.
Idorsia:n ISIN on CH0363463438. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Idorsia:n WKN on A2DTEB. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Idorsia:n ticker on IDIA.SW. Tämä pörssinoteeraus käytetään Idorsia-osakkeiden kauppaan pörssissä.
Idorsia osake
Idorsia vertaisryhmä
Idorsia Ticker
Idorsia FIGI
Kaikki tunnusluvut ja syvällinen analyysi Idorsia:sta
Meidän osakeanalyysimme Idorsia-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Idorsia:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: